Results 71 to 80 of about 42,691 (157)
Abstract Systemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin light chain fibrils, resulting in organ damage. Treatment is based on anti‐plasma cell regimens derived from multiple myeloma therapy.
Alexander Carpinteiro +15 more
wiley +1 more source
BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad +5 more
wiley +1 more source
A Case of Refractory Nephrotic Syndrome Complicated With Tuberculous Pleurisy and Literature Review
Nephrotic syndrome(NS) can be classified into steroid‐sensitive nephrotic syndrome (SSNS) and steroid‐resistant nephrotic syndrome (SRNS). Rifampicin is potentially leading to treatment resistance in NS.
Jiang‐min Wan +5 more
doaj +1 more source
ABSTRACT Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate and timely diagnosis. This retrospective cohort study assessed real‐world diagnostic workups
Muhamed Baljevic +7 more
wiley +1 more source
Abstract Background Although previous experimental studies showed that metabolic acidosis promoted muscle catabolism and impaired protein synthesis, few epidemiological studies reported an independent association between serum bicarbonate levels and muscle atrophy in patients with chronic kidney disease (CKD).
Nobuhisa Morimoto +13 more
wiley +1 more source
ABSTRACT Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases.
María Larrosa‐García +10 more
wiley +1 more source
Introduction: Focal segmental glomerulosclerosis (FSGS) is a pattern of kidney injury with diverse causes and pathogeneses, resulting in podocyte injury and depletion. It can be classified as primary, genetic, or secondary. Because FSGS classically has a
Gabriel Figueiredo +4 more
doaj +1 more source
ABSTRACT Aims The epithelial sodium channel ENaC consists of the subunits α, β, and γ and is activated at an individual channel level by proteolytic processing. Murine γENaC contains a distal polybasic tract 186RKRK mediating proteolytic ENaC activation by serine proteases in vitro.
Daniel Essigke +8 more
wiley +1 more source
Background Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events.
Ryosuke Saiki +11 more
doaj +1 more source
Non‐Isolated Dandy‐Walker Malformation: Exome Sequencing Efficacy and Phenotypic Expansions
Exome sequencing identified a diagnosis in 35% of 91 individuals with non‐isolated Dandy Walker malformation (DWM+). Only 24%–55% of these diagnoses could be made using a gene panel. We then demonstrated that DWM is a feature of disorders associated with ANKRD11, C2CD3, COL4A1, KMT2D, KRAS, OPHN1, SHOC2, SMARCB1, and WDR73.
Sarah Araji +4 more
wiley +1 more source

